At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET
Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability improvement, and raised 2026 guidance projecting 6-7% revenue growth and 7-13% adjusted EPS growth. The company exited a divestiture-impacted year with improved margins and cash flow, signaling operational strength.
- Q4 revenue: $157.9M, up 2.8% reported, 10.0% organic; driven by double-digit growth in Pain Treatments and Surgical Solutions
- Q4 GAAP EPS: $0.21 vs. $0.00 in prior year; Non-GAAP EPS: $0.24 vs. $0.26 in prior year
- Full-year 2025 revenue: $568.1M, down 0.9% reported (due to divestiture), up 7.5% organically
- Full-year 2025 GAAP EPS: $0.33 vs. loss of $0.56; Adjusted EPS: $0.68, up 21.4% YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access